Advertisement

Orthostatic intolerance and postural tachycardia syndrome: new insights into pathophysiology and treatment

Schwerpunkt

Abstract

Orthostatic intolerance is characterized by symptoms of light-headedness or syncope that is provoked upon standing or in an upright posture. It is most commonly caused by postural orthostatic tachycardia syndrome (POTS) or orthostatic hypotension (OH). Its pathophysiology is complex and commonly involves abnormal autonomic nervous system regulation, autoimmunity, a hyperadrenergic state, and hypovolemia. This article reviews the pathophysiology underlying orthostatic intolerance, as well as the current treatment available.

Keywords

Postural tachycardia syndrome Orthostatic hypotension Pathophysiology Autoimmunity Hypovolemia 

Orthostatische Intoleranz und posturales Tachykardiesyndrom: neue Erkenntnisse zur Pathophysiologie und Behandlung

Zusammenfassung

Orthostatische Intoleranz ist durch Symptome der Benommenheit oder Synkope charakterisiert, die durch Aufstehen oder aufrechtes Stehen provoziert werden. Ursache ist meist das posturale orthostatische Tachykardiesyndrom oder eine orthostatische Hypotonie. Die Pathophysiologie ist komplex und bezieht üblicherweise eine abnorme Regulation des autonomen Nervensystems, Autoimmunreaktionen, einen hyperadrenergen Zustand und Hypovolämie ein. In dieser Übersicht werden die Pathophysiologie, die der orthostatischen Intoleranz zugrunde liegt, und derzeit verfügbare Behandlungsmöglichkeiten zusammengefasst.

Schlüsselwörter

Posturales Tachykardiesyndrom Orthostatische Hypotonie Pathophysiologie Autoimmunität Hypovolämie 

Notes

Compliance with ethical guidelines

Conflict of interest

M. Ruzieh and B.P. Grubb declare that they have no competing interests.

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Fedorowski A, Melander O (2013) Syndromes of orthostatic intolerance: a hiddendanger. J Intern Med 273:322–335CrossRefPubMedGoogle Scholar
  2. 2.
    Grubb BP (2008) Postural tachycardia syndrome. Circulation 117:2814–2817CrossRefPubMedGoogle Scholar
  3. 3.
    Sheldon RS, Grubb BP, Olshansky B, Shen W‑K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA, Moak JP, Sandhu RK, Kanjwal K (2015) 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and Vasovagal syncope. Heart Rhythm 12:e41–e63CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M, Biaggioni I, Ertl A, Black B, Robertson D (2000) The neuropathic postural tachycardia syndrome. N Engl J Med 343:1008–1014CrossRefPubMedGoogle Scholar
  5. 5.
    Peltier AC, Garland E, Raj SR, Sato K, Black B, Song Y, Wang L, Biaggioni I, Diedrich A, Robertson D (2010) Distal sudomotor findings in postural tachycardia syndrome. Clin Auton Res 20:93–99CrossRefPubMedGoogle Scholar
  6. 6.
    Schondorf R, Low PA (1993) Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology 43:132–137CrossRefPubMedGoogle Scholar
  7. 7.
    Bonyhay I, Freeman R (2004) Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome. Circulation 110:3193–3198CrossRefPubMedGoogle Scholar
  8. 8.
    Jacob G, Shannon JR, Costa F, Furlan R, Biaggioni I, Mosqueda-Garcia R, Robertson RM, Robertson D (1999) Abnormal norepinephrine clearance and Adrenergic receptor sensitivity in idiopathic orthostatic intolerance. Circulation 99:1706–1712CrossRefPubMedGoogle Scholar
  9. 9.
    Hoeldtke RD, Dworkin GE, Gaspar SR, Israel BC (1989) Sympathotonic orthostatic hypotension. A report of four cases. Neurology 39(1):34–40CrossRefPubMedGoogle Scholar
  10. 10.
    Ruzieh M, Batizy L, Dasa O, Oostra C, Grubb B (2017) The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. Scand Cardiovasc J 5:243–247CrossRefGoogle Scholar
  11. 11.
    Blitshteyn S (2010) Postural tachycardia syndrome after vaccination with Gardasil. Eur J Neurol 17:e52–e52CrossRefPubMedGoogle Scholar
  12. 12.
    Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA (2000) Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic Neuropathies. N Engl J Med 343:847–855CrossRefPubMedGoogle Scholar
  13. 13.
    Yu X, Stavrakis S, Hill MA, Huang S, Reim S, Li H, Khan M, Hamlett S, Cunningham MW, Kem DC (2012) Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an “autoimmune” orthostatic hypotension: receptor autoantibodies in Orthostatic hypotension. J Am Soc Hypertens 6:40–47CrossRefPubMedGoogle Scholar
  14. 14.
    Gibbons CH, Freeman R (2009) Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. Auton Neurosci 146:8–12CrossRefPubMedGoogle Scholar
  15. 15.
    Gibbons CH, Vernino SA, Freeman R (2008) Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. Arch Neurol 65:213–217CrossRefPubMedGoogle Scholar
  16. 16.
    Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne DW, Robertson D (2005) Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 111:1574–1582CrossRefPubMedGoogle Scholar
  17. 17.
    Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D (2000) Orthostatic Intolerance and Tachycardia Associated with Norepinephrine-Transporter Deficiency. N Engl J Med 342:541–549CrossRefPubMedGoogle Scholar
  18. 18.
    Streeten DP, Kerr C, Kerr L, Prior J, Dalakos T (1972) Hyperbradykininism: a new orthostatic syndrome. Lancet 300:1048–1053CrossRefGoogle Scholar
  19. 19.
    Shibao C, Arzubiaga C, Roberts LJ, Raj S, Black B, Harris P, Biaggioni I (2005) Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 45:385–390CrossRefPubMedGoogle Scholar
  20. 20.
    Fu Q, VanGundy TB, Galbreath MM, Shibata S, Jain M, Hastings JL, Bhella PS, Levine BD (2010) Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol 55:2858–2868CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Jansen RM, Lipsitz LA (1995) Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 122:286–295CrossRefPubMedGoogle Scholar
  22. 22.
    Potter JF, Heseltine D, Hartley G, Matthews J, Macdonald IA, James OFW (1989) Effects of meal composition on the postprandial blood pressure, catecholamine and insulin changes in elderly subjects. Clin Sci 77:265–272CrossRefPubMedGoogle Scholar
  23. 23.
    Raj SR (2013) Postural Tachycardia Syndrome (POTS). Circulation 127:2336–2342CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ruzieh M, Baugh A, Dasa O, Parker RL, Perrault JT, Renno A, Karabin BL, Grubb B (2017) Effects of intermittent intravenous saline infusions in patients with medication—refractory postural tachycardia syndrome. J Interv Cardiac Electrophysiol 48:255–260CrossRefGoogle Scholar
  25. 25.
    Jacob G, Shannon JR, Black B, Biaggioni I, Mosqueda-Garcia R, Robertson RM, Robertson D (1997) Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 96:575–580CrossRefPubMedGoogle Scholar
  26. 26.
    Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ (2014) Droxidopa for neurogenic orthostatic hypotension. A randomized, placebo-controlled, phase 3 trial. Neurology 83:328–335CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ruzieh M, Dasa O, Pacenta A, Karabin B, Grubb B (2017) Droxidopa in the treatment of postural orthostatic tachycardia syndrome. Am J Ther 24:e157–e161CrossRefPubMedGoogle Scholar
  28. 28.
    Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, Dupont WD, Robertson D (2009) Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Less is more. Circulation 120:725–734CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ruzieh M, Sirianni N, Ammari Z, Dasa O, Alhazmi L, Karabin B, Grubb B (2017) Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. Pacing Clin Electrophysiol 40:1242–1245CrossRefPubMedGoogle Scholar
  30. 30.
    Gaffney FA, Lane LB, Pettinger W, Blomqvist CG (1983) Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia. Chest 83:436–438CrossRefPubMedGoogle Scholar
  31. 31.
    Kanjwal K, Karabin B, Sheikh M, Elmer L, Kanjwal Y, Saeed B, Grubb BP (2011) Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol 34:750–755CrossRefPubMedGoogle Scholar
  32. 32.
    Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB, Freedman RA, Hlatky MA, Naccarelli GV, Saksena S, Schlant RC, Silka MJ (1998) ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on pacemaker implantation)</i>. Circulation 97:1325–1335CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.CardiologyThe Pennsylvania State Heart and Vascular InstituteHersheyUSA
  2. 2.Division of Cardiovascular MedicineThe University of Toledo Medical CenterToledoUSA

Personalised recommendations